EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

miR-9 targeting RUNX1 improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS

Chuan Xiao, Qing Li, Jingjing Xiao, Xianjun Chen, Jia Yuan, Shuwen Li, Wei Li, Daixiu Gao, Lu Li, Ying Liu, Feng Shen

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Chuan Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: xc15973986196@163.co…. Hauptthemen laut MEDLINE: Acute Lung Injury, MicroRNAs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a clinical and pathophysiological complex syndrome with high mortality. Alveolar hypercoagulation and fibrinolytic inhibition constitute the core part of the pathophysiology of ARDS. miR-9 (microRNA-9a-5p) plays an important role in the pathogenesis of ARDS, but whether it regulates alveolar pro-coagulation and fibrinolysis inhibition in ARDS remains to be elucidated. We aimed to determine the contributing role of miR-9 on alveolar hypercoagulation and fibrinolysis inhibition in ARDS. METHODS: In the ARDS animal model, we first observed the miR-9 and runt-related transcription factor 1 (RUNX1) expression in lung tissue, the effects of miR-9 on alveolar hypercoagulation and fibrinolytic inhibition in ARDS rats, and the efficacy of miR-9 on acute lung injury. In the cell, alveolar epithelial cells type II (AECII) were treated with LPS, and the levels of miR-9 and RUNX1 were detected. Then we observed the effects of miR-9 on procoagulant and fibrinolysis inhibitor factors in cells. Finally, we explored whether the efficacies of miR-9 were associated with RUNX1; we also preliminarily examined the miR-9 and RUNX1 levels in plasma in patients with ARDS. RESULTS: In ARDS rats, miR-9 expression decreased, but RUNX1 expression increased in the pulmonary tissue of ARDS rats. miR-9 displayed to attenuate lung injury and pulmonary wet/dry ratio. Study results in vivo demonstrated that miR-9 ameliorated alveolar hypercoagulation and fibrinolysis inhibition and attenuated the collagen III expressions in tissue. miR-9 also inhibited NF-κB signaling pathway activation in ARDS. In LPS-induced AECII, the expression changes of both miR-9 and RUNX1 were similar to those in pulmonary tissue in the animal ARDS model. miR-9 effectively inhabited tissue factor (TF), plasma activator inhibitor (PAI-1) expressions, and NF-κB activation in LPS-treated ACEII cells. Besides, miR-9 directly targeted RUNX1, inhibiting TF and PAI-1 expression and attenuating NF-κB activation in LPS-treated AECII cells. Clinically, we preliminarily found that the expression of miR-9 was significantly reduced in ARDS patients compared to non-ARDS patients. CONCLUSION: Our experimental data indicate that by directly targeting RUNX1, miR-9 improves alveolar hypercoagulation and fibrinolysis inhibition via suppressing NF-κB pathway activation in LPS-induced rat ARDS, implying that miR-9/RUNX1 is expected to be a new therapeutic target for ARDS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryMicroRNAsAnimalsRatsCore Binding Factor Alpha 2 SubunitFibrinolysisLipopolysaccharidesNF-kappa BPlasminogen Activator Inhibitor 1

Stichwörter der Autor:innen

Acute respiratory distress syndromeAlveolar hypercoagulationFibrinolytic inhibitionRunt-related transcription factor 1microRNA-9

Substanzen

Core Binding Factor Alpha 2 SubunitLipopolysaccharidesMicroRNAsMIRN9 microRNA, ratNF-kappa BPlasminogen Activator Inhibitor 1Runx1 protein, rat

Autor:innen und Institutionen

  • Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: xc15973986196@163.com.
  • Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: 2538853252@qq.com.
  • Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang, China. Electronic address: 641720046@qq.com.
  • Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: chenxj@gmc.edu.cn.
  • Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: 1006783013@qq.com.
  • Department of Critical Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, China. Electronic address: 382574528@qq.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiao, C., Li, Q., Xiao, J., Chen, X., Yuan, J., Li, S., Li, W., Gao, D., Li, L., Liu, Y., & Shen, F. (2023). miR-9 targeting RUNX1 improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110318

Vancouver

Xiao C, Li Q, Xiao J, Chen X, Yuan J, Li S, et al. miR-9 targeting RUNX1 improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110318

BibTeX
@article{Xiao2023,
  author = {Xiao, Chuan and Li, Qing and Xiao, Jingjing and Chen, Xianjun and Yuan, Jia and Li, Shuwen and Li, Wei and Gao, Daixiu and Li, Lu and Liu, Ying and Shen, Feng},
  title = {miR-9 targeting RUNX1 improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110318}
}
Kostenlos starten →